Other/Multi
Other/Multi
Decoding clinical trial jargon: Helping people understand how safety and quality of life are assessed in cancer trials
Burkholder J, Burkholder A, DeCotiis G, FitzGibbon H, Mehta P.
Future Oncol. 2025;21(1):5-10. doi: 10.1080/14796694.2024.2422808.
Quizartinib
Other/Multi
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia
Vaddady P, Glatard A, Smania G, et al.
Clin Transl Sci. 2024;17(12):e70074. doi: 10.1111/cts.70074.
T-DXd
Colorectal Cancer
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: Biomarker analyses of DESTINY-CRC01
Siena S, Raghav K, Masuishi T, et al.
Nat Commun. 2024;15(1):10213. doi: 10.1038/s41467-024-53223-3.
Dato-DXd
Breast Cancer
Anti-tumor activity and biomarker analysis for TROP2 antibody-drug conjugate datopotamab deruxtecan in patient-derived breast cancer xenograft models
Meric-Bernstam F, Yuca E, Evans KW, et al.
Clin Cancer Res. 2024. doi: 10.1158/1078-0432.CCR-24-1948.
Edoxaban
Cardiovascular - VTE
Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients
Zou P, Atluri A, Chang P, et al.
CPT Pharmacometrics Syst Pharmacol. 2025;14(1):118-129. doi: 10.1002/psp4.13248.
Valemetostat
Other/Multi
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
Zinzani PL, Izutsu K, Mehta-Shah N, et al.
Lancet Oncol. 2024;25(12):1602-1613. doi: 10.1016/S1470-2045(24)00503-5
Valemetostat
Other/Multi
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: A first-in-human, multicentre, open-label, single-arm, phase 1 study
Maruyama D, Jacobsen E, Porcu P, et al.
Lancet Oncol. 2024;25(12):1589-1601. doi: 10.1016/S1470-2045(24)00502-3
Edoxaban
Cardiovascular - AF
Bioprosthetic valve positions in patients with atrial fibrillation- insights from the BPV-AF registry
Obayashi Y, Miyake M, Takegami M, et al.
Circ Rep. 2024;6(11):521-528. doi: 10.1253/circrep.CR-24-0110.
T-DXd
Gastric Cancer
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)
Kawakami H, Nakanishi K, Makiyama A, et al.
Gastric Cancer. 2025;28(1):51-61. doi: 10.1007/s10120-024-01555-w
HER3-DXd
Lung Cancer
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples
Soo RA, Clinthorne G, Santhanagopal A, et al.
Future Oncol. 2024;20(37):2961-2970. doi: 10.1080/14796694.2024.2398983. Epub 2024.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29